These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

381 related items for PubMed ID: 24708193

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
    Chang HT, Hu C, Chiu YL, Peng NJ, Liu RS.
    PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
    [Abstract] [Full Text] [Related]

  • 43. Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage Hodgkin lymphoma.
    Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M.
    J Clin Oncol; 2014 Jun 10; 32(17):1776-81. PubMed ID: 24799482
    [Abstract] [Full Text] [Related]

  • 44. Impact of ¹⁸F-FDG PET/CT for detecting recurrence of medullary thyroid carcinoma.
    Ozkan E, Soydal C, Kucuk ON, Ibis E, Erbay G.
    Nucl Med Commun; 2011 Dec 10; 32(12):1162-8. PubMed ID: 21946617
    [Abstract] [Full Text] [Related]

  • 45. ABVD alone and a PET scan complete remission negates the need for radiologic surveillance in early-stage, nonbulky Hodgkin lymphoma.
    Hartridge-Lambert SK, Schöder H, Lim RC, Maragulia JC, Portlock CS.
    Cancer; 2013 Mar 15; 119(6):1203-9. PubMed ID: 23132361
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: status in a single center.
    El-Galaly T, Prakash V, Christiansen I, Madsen J, Johansen P, Boegsted M, Johnsen HE, Bukh A.
    Leuk Lymphoma; 2011 Apr 15; 52(4):597-603. PubMed ID: 21314488
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Fluorine-18 fluorodeoxyglucose PET/CT patterns of extranodal involvement in patients with Non-Hodgkin lymphoma and Hodgkin's disease.
    Even-Sapir E, Lievshitz G, Perry C, Herishanu Y, Lerman H, Metser U.
    Radiol Clin North Am; 2007 Jul 15; 45(4):697-709, vii. PubMed ID: 17706534
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ, Kresnik E, Gasser J, Kumnig G, Igerc I, Mikosch P, Lind P.
    Invest Radiol; 2003 May 15; 38(5):250-6. PubMed ID: 12750613
    [Abstract] [Full Text] [Related]

  • 53. Performance of CT Compared with 18F-FDG PET in Predicting the Efficacy of Nivolumab in Relapsed or Refractory Hodgkin Lymphoma.
    Mokrane FZ, Chen A, Schwartz LH, Morschhauser F, Stamatoullas A, Schiano de Colella JM, Vercellino L, Casasnovas O, Chauchet A, Delmer A, Nicolas-Virelizier E, Ghesquières H, Moles-Moreau MP, Schmitt A, Duléry R, Bouabdallah K, Borel C, Touati M, Deau-Fischer B, Peyrade F, Seban RD, Manson G, Houot R, Dercle L.
    Radiology; 2020 Jun 15; 295(3):651-661. PubMed ID: 32286191
    [Abstract] [Full Text] [Related]

  • 54. [Clinical value of FDG PET for therapy monitoring of malignant lymphoma--results of a retrospective study in 72 patients].
    Cremerius U, Fabry U, Kröll U, Zimny M, Neuerburg J, Osieka R, Büll U.
    Nuklearmedizin; 1999 Jun 15; 38(1):24-30. PubMed ID: 9987778
    [Abstract] [Full Text] [Related]

  • 55. Direct comparison of FDG PET and CT findings in patients with lymphoma: initial experience.
    Tatsumi M, Cohade C, Nakamoto Y, Fishman EK, Wahl RL.
    Radiology; 2005 Dec 15; 237(3):1038-45. PubMed ID: 16304117
    [Abstract] [Full Text] [Related]

  • 56. Whole body positron emission tomography in the treatment of Hodgkin disease.
    Hueltenschmidt B, Sautter-Bihl ML, Lang O, Maul FD, Fischer J, Mergenthaler HG, Bihl H.
    Cancer; 2001 Jan 15; 91(2):302-10. PubMed ID: 11180075
    [Abstract] [Full Text] [Related]

  • 57. Detection and restaging of residual and/or recurrent nasopharyngeal carcinoma after chemotherapy and radiation therapy: comparison of MR imaging and FDG PET/CT.
    Comoretto M, Balestreri L, Borsatti E, Cimitan M, Franchin G, Lise M.
    Radiology; 2008 Oct 15; 249(1):203-11. PubMed ID: 18710963
    [Abstract] [Full Text] [Related]

  • 58. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma.
    Sasaki M, Kuwabara Y, Koga H, Nakagawa M, Chen T, Kaneko K, Hayashi K, Nakamura K, Masuda K.
    Ann Nucl Med; 2002 Jul 15; 16(5):337-45. PubMed ID: 12230093
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.